Drug development projects of Motorpharma
Our research
We at Motorpharma are keen on developing new generation drug candidates that open new dimensions to drug development. Our major pipeline project is MPH-220 that might be able to treat patients suffering from spasticity.
About 10% of the world suffers from the excruciating symptoms of spasticity caused by low back pain or neuro injury related diseases. Our drug development project is aiming at targeting directly the effector molecule of muscle contraction with drug candidates.
News